Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659090 | 0.83 | ATM (0.57) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL9597587 | 0.80 | ATM (0.63) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL9598426 | 0.79 | ATM (0.61) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL3823640 | 0.78 | ATM (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL2908675 | 0.78 | L3MBTL1 (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL3639574 | 0.78 | PDPK1 (0.54) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL873512 | 0.78 | CYP1A2 (0.54) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL6598600 | 0.78 | ATM (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL13977557 | 0.78 | ATM (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 | |
| SCHEMBL29526856 | 0.78 | ATM (0.51) | ATML3MBTL1CYP1A2CYP2A6PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4785104-A | CARDIOVASCULAR DISORDERS, INOTROPIC AGENTS | EGIS GYOGYSZERGYAR (HU) | 1988-11-15 | — | — | US | claimed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| CN-114206866-A | Prostaglandin E2Receptor 4 antagonists and uses thereof | 泰昂治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-4785104-A | CARDIOVASCULAR DISORDERS, INOTROPIC AGENTS | EGIS GYOGYSZERGYAR (HU) | 1988-11-15 | — | — | US | disclosed |
| EP-0110372-B1 | 1-PHENYLISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-10 | — | — | EP | disclosed |
| US-4547508-A | 1-Phenylisoquinoline derivatives, pharmaceutical products containing these compounds and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-15 | — | — | US | disclosed |
| EP-0110372-A1 | 1-Phenylisoquinoline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-13 | — | — | EP | disclosed |
| US-4287197-A | ALSO USEFUL AS ANALGESICS, ANTIPYRETICS AND ANTIINFLAMMATORY AGENTS | RHONE-POULENC INDUSTRIES (FR) | 1981-09-01 | — | — | US | disclosed |
| US-4261992-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE POULENC INDUSTRIES (FR) | 1981-04-14 | — | — | US | disclosed |
| US-4261993-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE POULENC INDUSTRIES (FR) | 1981-04-14 | — | — | US | disclosed |
| US-4108999-A | ANTIULCER AGENTS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-22 | — | — | US | disclosed |
| US-4064247-A | ANALGESIC, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1977-12-20 | — | — | US | disclosed |
| US-3891654-A | 6,7 Substituted 3-hydroxymethyl- 1 phenyl, benzyl or phenylethyl substituted isoquinolines | ALBERT & ROWLAND | 1975-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | ATM 4047/4885L3MBTL1 4529/4885CYP1A2 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.